MSCP MENOPAUSE SOCIETY CERTIFIED PRACTITIONER
CERTIFICATION EXAM 2026 COMPLETE 300 PRACTICE
QUESTIONS WITH VERIFIED ANSWERS & RATIONALES |
This comprehensive practice exam bank features highly realistic
multiple-choice questions designed to align perfectly with the 2026
Menopause Society Certified Practitioner (MSCP) blueprint. Every
question includes a verified correct answer and a robust, bolded
scientific rationale to ensure mastery of hormonal physiology, MHT
safety parameters, and long-term bone and cardiovascular health. It
serves as an essential, high-density study companion tailored to help
clinicians pass the official NAMS/Menopause Society board
examination on their first attempt.
Question 1
A 51-year-old woman presents with moderate-to-severe hot
flashes and night sweats that disrupt her sleep. She has an
intact uterus and no significant past medical history. Which of
the following is the most appropriate initial hormone therapy
regimen?
A. Conjugated equine estrogens (CEE) 0.45 mg daily alone
B. Continuous combined oral estradiol 1 mg / drospirenone 0.5
mg daily
C. Transdermal estradiol 0.05 mg patch weekly alone
D. Oral micronized progesterone 100 mg daily alone
Answer: B
Rationale: In women with an intact uterus, systemic
estrogen therapy must always be paired with a progestogen
,to protect against endometrial hyperplasia and carcinoma.
Continuous combined regimens provide both endometrial
protection and effective vasomotor symptom relief. Options
A and C are incorrect because estrogen monotherapy is
contraindicated in women with a uterus. Option D alone is
not the standard first-line choice for complete vasomotor
symptom relief compared to combination therapy.
Question 2
According to the Menopause Society guidelines, what is the
primary physiological mechanism driving the "late menopausal
transition" stage (STRAW+10 Stage -1)?
A. A sustained, permanent elevation of progesterone levels
B. An increase in the length of cycles followed by skipped cycles
of 60 days or more
C. A complete depletion of primordial follicles in the ovary
D. A decline in follicle-stimulating hormone (FSH) to prepubertal
levels
Answer: B
Rationale: The late menopausal transition (Stage -1 on the
STRAW+10 scale) is characterized by advanced variable
cycle length, specifically characterized by skipped cycles
or periods of amenorrhea lasting 60 days or longer. Follicle-
stimulating hormone (FSH) levels fluctuate significantly but
are generally elevated, not low. Complete primordial follicle
depletion defines postmenopause, not the transition.
,Question 3
A 47-year-old patient reports a sudden change in her menstrual
bleeding pattern, with cycles shortening to 21 days and bleeding
becoming heavy and prolonged. She has no other symptoms.
What is the most appropriate next diagnostic step?
A. Reassure her that this is normal perimenopause and advise
waiting
B. Perform an endometrial biopsy to rule out endometrial
hyperplasia or malignancy
C. Order a pelvic ultrasound and serum thyroid-stimulating
hormone (TSH) level
D. Immediately initiate high-dose oral contraceptive pills
Answer: C
Rationale: Abnormal uterine bleeding (AUB) in a
perimenopausal woman must be thoroughly evaluated
before starting hormonal treatment. Initial evaluation
should look for structural causes (via transvaginal
ultrasound) and systemic causes like thyroid dysfunction
(via TSH). An endometrial biopsy (Option B) is indicated if
the ultrasound shows an irregular/thickened strip, or if she
has high-risk factors (e.g., obesity, age over 45 with
persistent AUB), but structural and endocrine rule-outs are
standard first steps.
Question 4
, Which of the following biomarkers is considered the most
reliable and earliest indicator of declining ovarian reserve during
the early menopausal transition?
A. Anti-Müllerian Hormone (AMH)
B. Luteinizing Hormone (LH)
C. Estrone (E1)
D. Inhibin A
Answer: A
Rationale: Anti-Müllerian Hormone (AMH) is produced by
the granulosa cells of early-stage follicles. It declines
significantly before an increase in FSH is observed, making
it one of the earliest and most sensitive markers of a
declining pool of oocytes, though clinical staging is
primarily based on menstrual cycles.
Question 5
A 53-year-old woman requests non-hormonal treatment for
severe vasomotor symptoms due to a personal history of
estrogen-receptor-positive breast cancer. Which of the following
non-hormonal prescription therapies has been FDA-approved
specifically to treat moderate-to-severe vasomotor symptoms?
A. Gabapentin
B. Clonidine
C. Paroxetine mesylate
D. Venlafaxine
Answer: C
CERTIFICATION EXAM 2026 COMPLETE 300 PRACTICE
QUESTIONS WITH VERIFIED ANSWERS & RATIONALES |
This comprehensive practice exam bank features highly realistic
multiple-choice questions designed to align perfectly with the 2026
Menopause Society Certified Practitioner (MSCP) blueprint. Every
question includes a verified correct answer and a robust, bolded
scientific rationale to ensure mastery of hormonal physiology, MHT
safety parameters, and long-term bone and cardiovascular health. It
serves as an essential, high-density study companion tailored to help
clinicians pass the official NAMS/Menopause Society board
examination on their first attempt.
Question 1
A 51-year-old woman presents with moderate-to-severe hot
flashes and night sweats that disrupt her sleep. She has an
intact uterus and no significant past medical history. Which of
the following is the most appropriate initial hormone therapy
regimen?
A. Conjugated equine estrogens (CEE) 0.45 mg daily alone
B. Continuous combined oral estradiol 1 mg / drospirenone 0.5
mg daily
C. Transdermal estradiol 0.05 mg patch weekly alone
D. Oral micronized progesterone 100 mg daily alone
Answer: B
Rationale: In women with an intact uterus, systemic
estrogen therapy must always be paired with a progestogen
,to protect against endometrial hyperplasia and carcinoma.
Continuous combined regimens provide both endometrial
protection and effective vasomotor symptom relief. Options
A and C are incorrect because estrogen monotherapy is
contraindicated in women with a uterus. Option D alone is
not the standard first-line choice for complete vasomotor
symptom relief compared to combination therapy.
Question 2
According to the Menopause Society guidelines, what is the
primary physiological mechanism driving the "late menopausal
transition" stage (STRAW+10 Stage -1)?
A. A sustained, permanent elevation of progesterone levels
B. An increase in the length of cycles followed by skipped cycles
of 60 days or more
C. A complete depletion of primordial follicles in the ovary
D. A decline in follicle-stimulating hormone (FSH) to prepubertal
levels
Answer: B
Rationale: The late menopausal transition (Stage -1 on the
STRAW+10 scale) is characterized by advanced variable
cycle length, specifically characterized by skipped cycles
or periods of amenorrhea lasting 60 days or longer. Follicle-
stimulating hormone (FSH) levels fluctuate significantly but
are generally elevated, not low. Complete primordial follicle
depletion defines postmenopause, not the transition.
,Question 3
A 47-year-old patient reports a sudden change in her menstrual
bleeding pattern, with cycles shortening to 21 days and bleeding
becoming heavy and prolonged. She has no other symptoms.
What is the most appropriate next diagnostic step?
A. Reassure her that this is normal perimenopause and advise
waiting
B. Perform an endometrial biopsy to rule out endometrial
hyperplasia or malignancy
C. Order a pelvic ultrasound and serum thyroid-stimulating
hormone (TSH) level
D. Immediately initiate high-dose oral contraceptive pills
Answer: C
Rationale: Abnormal uterine bleeding (AUB) in a
perimenopausal woman must be thoroughly evaluated
before starting hormonal treatment. Initial evaluation
should look for structural causes (via transvaginal
ultrasound) and systemic causes like thyroid dysfunction
(via TSH). An endometrial biopsy (Option B) is indicated if
the ultrasound shows an irregular/thickened strip, or if she
has high-risk factors (e.g., obesity, age over 45 with
persistent AUB), but structural and endocrine rule-outs are
standard first steps.
Question 4
, Which of the following biomarkers is considered the most
reliable and earliest indicator of declining ovarian reserve during
the early menopausal transition?
A. Anti-Müllerian Hormone (AMH)
B. Luteinizing Hormone (LH)
C. Estrone (E1)
D. Inhibin A
Answer: A
Rationale: Anti-Müllerian Hormone (AMH) is produced by
the granulosa cells of early-stage follicles. It declines
significantly before an increase in FSH is observed, making
it one of the earliest and most sensitive markers of a
declining pool of oocytes, though clinical staging is
primarily based on menstrual cycles.
Question 5
A 53-year-old woman requests non-hormonal treatment for
severe vasomotor symptoms due to a personal history of
estrogen-receptor-positive breast cancer. Which of the following
non-hormonal prescription therapies has been FDA-approved
specifically to treat moderate-to-severe vasomotor symptoms?
A. Gabapentin
B. Clonidine
C. Paroxetine mesylate
D. Venlafaxine
Answer: C
